B Cell based Inhibition by Antigen Assay Service
Creative Biolabs' B cell-based inhibition by antigen assay delivers a clear, actionable solution for your antibody discovery program. The key problem we solve is the critical gap between simple binding affinity and true functional efficacy. Creative Biolabs provides a robust platform to confirm that your candidate antibodies not only bind to the target antigen but also effectively block its biological function on a native cell surface. This ensures that you advance only the most promising candidates to the next stage, saving significant time and resources.
Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
The Valuable Inhibition Assay for Epitope Identification
One of the most important mechanisms of action of antibodies for therapies is the antibody-based inhibition function, such as inhibiting key signaling transduction for tumor cell growth. In prostate cancer, antibodies are developed to block the prostate-specific antigen (PSA) binding to a1-antichymotrypsin (ACT). Immune checkpoint antibodies are developed to inhibit the interaction of PD-1 on T cells with PD-L1 on tumor cells. The binding interaction between antibody and epitope peptide inhibits the binding of antigens of homologous origin to the same antibody. This antigen inhibition assay has become a classical method for identifying antigenic epitopes within antigens.
To obtain further information regarding the capabilities of this service, request a consultation.
Fig.1 Potential action mechanisms of monoclonal antibody targeting the HER2 receptor.1
What We Can Offer
|
Services
|
Description & Features
|
|
Antigen Synthesis & Purification
|
High-quality recombinant protein antigens purified via chromatography. Purity and concentration are verified and documented for reliability.
|
|
Antibody Production
|
Custom polyclonal, monoclonal antibody, and serum production. Sourced from immunized animals (mice, rabbits, goats) or infected patient sera.
|
|
Linear Peptide Library Generation
|
Overlapping peptide libraries covering target protein sequences. Optional terminal tags (e.g., Biotin) for easy immobilization during screening.
|
|
Dominant Epitope Screening
|
High-throughput ELISA-based screening to identify strong binding B-cell epitopes using optimized coating conditions and peptide libraries.
|
|
Antigen Inhibition Assay
|
Customizable assays to measure antigen/peptide inhibition of antibody binding or function. Quantifies the inhibition rate via antibody-antigen interaction.
|
Antibody-mediated Antigen Inhibition Assay Service at Creative Biolabs
Creative Biolabs offers custom characterization services of cancer-associated epitopes by synthesizing overlapping peptide libraries derived from an antigen and screening them against antigen-specific antibodies.
Highlights
A Legacy of Expertise
Creative Biolabs provides a service that is both scientifically rigorous and commercially focused, backed by over two decades of expertise in antibody discovery and development.
Scientifically Rigorous
We are dedicated to producing superior results through our commitment to scientific excellence, ensuring that every project is conducted with precision and accuracy.
Therapeutically Focused
Our service is designed to generate highly predictive data, ensuring your antibody candidates are not just binders, but truly functional therapeutics that accelerate your path to a breakthrough.
Reliable and Proven
Our B cell-based inhibition by antigen assay has a proven track record of helping clients successfully identify and validate potent antibody leads.
Prospective clients are invited to contact us to receive a comprehensive quotation. Get a quote today.
Customer Reviews
-
Highly predictive data
Using Creative Biolabs' B cell-based inhibition by antigen assay in our research has significantly improved our ability to select functionally active antibodies for our therapeutic program. - J. M***n.
-
Unmatched specificity
The use of native B cells in the assay provides a level of confidence in antibody specificity that traditional binding assays simply cannot match. It's an essential tool for any serious antibody discovery team. - S. H***y.
FAQs
What is the primary advantage of this assay compared to traditional ELISA or SPR?
Our assay uses native B cells, which present the antigen in its natural, membrane-bound form. This provides a more physiologically relevant context than purified proteins in a well plate, allowing us to screen for true functional inhibitors and reduce false positives.
How does this assay help with epitope mapping?
While our primary goal is functional inhibition, the assay can provide valuable insights into epitope relevance. By demonstrating that an antibody can block antigen binding on a native cell, we confirm its ability to bind to an accessible and functionally relevant epitope, a crucial step that complements and validates peptide-based epitope mapping.
Related Services
Affinity Measurement
We can provide precise and rapid determination of the affinity, kinetics, and concentration of biomolecular interactions using advanced platforms like SPR, BLI, and MST. This service helps you to characterize the binding properties of your antibodies in detail.
Learn More →
Kinetic Analysis of Overexpressed Cytokine Secretion
Our functional assays can be used to measure the real-time secretion of cytokines and other signaling molecules, providing a direct and quantitative measure of a B cell's biological response to antigen stimulation and antibody inhibition.
Learn More →
How to Contact Us
For different backgrounds of cancer antigens and different objectives of epitope analysis demands, our experts can design special assays for each client's research. Creative Biolabs is devoted to offering the most reliable and efficient epitope analysis service to help clients develop desired antibodies faster. Please contact us for more detailed information.
Reference
-
Lv, Quanxia et al. "Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer." International journal of molecular sciences vol. 17,12 2095. 14 Dec. 2016. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms17122095
For Research Use Only | Not For Clinical Use
